1. Li Z, Wang Y, He J, et al. Serological thymidine kinase 1 is a prognostic factor in oesophageal, cardial and lung carcinomas. Eur J Cancer Prev. 2010;19(4):313–8.
2. Zhang F, Li H, Pendleton AR, et al. Thymidine kinase 1 immunoassay: a potential marker for breast cancer. Cancer Detect Prev. 2001;25(1):8–15.
3. Aufderklamm S, Todenhöfer T, Gakis G, et al. Thymidine kinase and cancer monitoring. Cancer Lett. 2012;316(1):6–10.
4. Guan H, Sun Y, Zan Q, et al. Thymidine kinase 1 expression in atypical ductal hyperplasia significantly differs from usual ductal hyperplasia and ductal carcinoma in situ: a useful tool in tumor therapy management. Mol Med Rep. 2009;2(6):923–9.
5. Xu XH, Zhang YM, Shu XH, et al. Serum thymidine kinase 1 reflects the progression of pre-malignant and malignant tumors during therapy. Mol Med Rep. 2008;1(5):705–11.